Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
Abstract Background There is considerable variability in COVID-19 outcomes amongst younger adults—and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium.Method The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors.Findings We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors.Interpretation The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality—and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management.Funding Funding was obtained by each of the participating cohorts individually..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 25. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| doi: |
10.1101/2021.03.07.21252875 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020123515 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020123515 | ||
| 003 | DE-627 | ||
| 005 | 20230429085053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210315s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.03.07.21252875 |2 doi | |
| 035 | |a (DE-627)XBI020123515 | ||
| 035 | |a (biorXiv)10.1101/2021.03.07.21252875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Nakanishi, Tomoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background There is considerable variability in COVID-19 outcomes amongst younger adults—and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium.Method The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors.Findings We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors.Interpretation The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality—and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management.Funding Funding was obtained by each of the participating cohorts individually. | ||
| 700 | 1 | |a Pigazzini, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Degenhardt, Frauke |e verfasserin |4 aut | |
| 700 | 1 | |a Cordioli, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Butler-Laporte, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Maya-Miles, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Nafría-Jiménez, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Bouysran, Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Niemi, Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Palom, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Ellinghaus, David |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Atlas |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Bueno, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rolker, Selina |e verfasserin |4 aut | |
| 700 | 1 | |a Amitano, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Tato, Luisa Roade |e verfasserin |4 aut | |
| 700 | 1 | |a Fava, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Spinner, Christoph D. |e verfasserin |4 aut | |
| 700 | 1 | |a Prati, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardo, David |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Darcis, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Cadenas, Israel |e verfasserin |4 aut | |
| 700 | 1 | |a Holter, Jan Cato |e verfasserin |4 aut | |
| 700 | 1 | |a Banales, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Frithiof, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Kiryluk, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Duga, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Asselta, Rosanna |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Alexandre C |e verfasserin |4 aut | |
| 700 | 1 | |a Romero-Gómez, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Bujanda, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Hov, Johannes R. |e verfasserin |4 aut | |
| 700 | 1 | |a Migeotte, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Renieri, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Planas, Anna M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ludwig, Kerstin U. |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmouni, Souad |e verfasserin |4 aut | |
| 700 | 1 | |a Alarcón-Riquelme, Marta E. |e verfasserin |4 aut | |
| 700 | 1 | |a Schulte, Eva C. |e verfasserin |4 aut | |
| 700 | 1 | |a Franke, Andre |e verfasserin |4 aut | |
| 700 | 1 | |a Karlsen, Tom H |e verfasserin |4 aut | |
| 700 | 1 | |a Valenti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Zeberg, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, J. Brent |e verfasserin |4 aut | |
| 700 | 1 | |a Ganna, Andrea |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 25. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:25 |g month:05 |
| 856 | 4 | 0 | |u https://doi.org/10.1172/JCI152386 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.03.07.21252875 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 25 |c 05 | ||
| 953 | |2 045F |a 570 | ||